# Early Parkinson’s Blood Biomarkers
Chalmers University Identifies Early Parkinson’s Blood Marker

By Kanesa David | Written with AI assistance | Published 2026-02-02 | Tech
Source: Trend Hunter, https://www.trendhunter.com/trends/chalmers-university
References: [sciencedaily](https://www.sciencedaily.com/releases/2026/01/260129080424.htm) & [chalmers.se](https://www.chalmers.se/en/)

![Early Parkinson’s Blood Biomarkers](https://cdn.trendhunterstatic.com/thumbs/599/chalmers-university.jpeg)

Researchers at Chalmers University of Technology in Sweden, in collaboration with Oslo University Hospital, identified early-stage Parkinson’s disease biomarkers detectable in standard blood samples. The study focused on subtle shifts in how cells handle DNA repair and respond to stress, revealing a brief, pre-symptomatic window when Parkinson’s leaves a measurable molecular trail. These patterns appeared before classic motor symptoms, when brain cells had not yet undergone extensive damage.

Using machine-learning analysis, the team mapped a distinct gene-activity signature tied to DNA repair and cellular stress pathways. This signature consistently showed up in people in the prodromal, or early, phase of Parkinson’s but disappeared once motor symptoms had fully developed. Because the biomarkers are blood-based rather than reliant on spinal fluid taps or brain imaging, they suggest a more scalable route to routine screening.

For consumers and healthcare systems, blood tests built on this research could eventually enable earlier detection and more proactive treatment planning. Earlier identification would support interventions while the brain is still relatively preserved, aligning with a broader shift toward preventive, data-driven medicine. What sets this work apart is its focus on a narrow, early biomarker window that is both biologically specific and compatible with everyday clinical blood testing.

Image Credit: Nicola Pietro Montaldo